Navigation Links
Investigating how spiders spin their silk, researchers unravel a key step
Date:5/12/2010

Five times the tensile strength of steel and triple that of the currently best synthetic fibers: Spider silk is a fascinating material. But no one has thus far succeeded in producing the super fibers synthetically. How do spiders form long, highly stable and elastic fibers from the spider silk proteins stored in the silk gland within split seconds? Scientists from the Technische Universitaet Muenchen (TUM) and the University of Bayreuth have now succeeded in unraveling the secret. They present their results in the current issue of the prestigious scientific journal Nature.

"The high elasticity and extreme tensile strength of natural spider silk are unmatched, even by fibers produced from pure spider silk proteins," says Professor Horst Kessler, Carl-von-Linde Professor at the Institute for Advanced Study of the TU Muenchen. That highlights a key question in the artificial production of stable spider silk fibers: How do spiders manage to keep the high concentrations of raw material available in the silk gland, ready to produce the high tensile strength fiber at a moment's notice. Thomas Scheibel has been pursuing the secret of spider silk for years, until 2007 at TUM and since then at the University of Bayreuth.

Spider silk consists of protein molecules, long chains comprising thousands of amino-acid elements. X-ray structure analyses show that the finished fiber has areas in which several protein chains are interlinked via stable physical connections. These connections provide the high stability. Between these connections are unlinked areas that give the fibers their great elasticity.

The situation within the silk gland is, however, very different: The silk proteins are stored in high concentrations in an aqueous environment, awaiting deployment. The areas responsible for interlinking may not approach each other too closely; otherwise the proteins would clump up instantaneously. Hence, these molecules must have some kind of special storage configuration.

X-ray structure analysis, which is so successful in other domains, was of little help here, since it can only be used to analyze crystals. And up to the instant in which the solid silk fiber is formed, everything takes place in solution. The method of choice was therefore nuclear magnetic resonance spectroscopy (NMR). Using the equipment of the Bavarian NMR Center, Franz Hagn, a biochemist from Horst Kessler's work group at the Institute for Advanced Study (TUM-IAS) at the TU Muenchen, managed to unravel the structure of a control element responsible for the formation of the solid fiber. Now the researchers could, together with Lukas Eisoldt and John Hardy from Thomas Scheibel's group, shed light on this control element's mode of operation.

"Under storage conditions in the silk gland these control domains are connected pair-wise in such a way that the interlinking areas of both chains can not lie parallel to each other," Thomas Scheibel explains. "Interlinking is thus effectively prevented." The protein chains are stored with the polar areas on the outside and the hydrophobic parts of the chain on the inside, ensuring good solubility in the aqueous environment.

When the protected proteins enter the spinning duct, they encounter an environment with an entirely different salt concentration and composition. This renders two salt bridges of the control domain unstable, and the chain can unfold. Furthermore, the flow in the narrow spinning duct results in strong shear forces. The long protein chains are aligned in parallel, thus placing the areas responsible for interlinking side by side. The stable spider silk fiber is formed.

"Our results have shown that the molecular switch we discovered at the C-terminal end of the protein chain is decisive, both for safe storage and for the fiber formation process," says Franz Hagn. An important foundation for these results was established through cooperation of Thomas Scheibel's group with Professor Andreas Bausch's workgroup at the Physics Department at TUM. Using microsystem technology, they developed an artificial spinning duct. Meanwhile the Bayreuth scientists are working intensively to develop a biomimetic spinning apparatus, within the framework of a federally supported joint project with industrial partners. The potential applications are countless, from resorbable surgical suture material to technical fibers for the automotive industry.

The research has been supported through the provision of testing and measuring time by the Bavarian NMR Center, through the Deutsche Forschungsgemeinschaft (DFG), the Excellence Cluster Center for Integrated Protein Science Munich (CIPSM) and the Institute for Advanced Study at the TU Muenchen, where Horst Kessler has been working as Senior Fellow since becoming Emeritus. Franz Hagn's work is funded by the Bayerisches Elitenetzwerk CompInt, co-author John G. Hardy from the Alexander von Humboldt Foundation.


'/>"/>

Contact: Andreas Battenberg
battenberg@zv.tum.de
49-892-891-0510
Technische Universitaet Muenchen
Source:Eurekalert

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
3. Hagens Berman Sobol Shapiro Investigating CellCyte
4. Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
8. Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
9. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
10. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
11. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):